PsART-International is a web-based registry of PsA patients under routine care in Turkey, Italy, and Canada. It includes detailed disease history about the type and onset of skin and joint disease. “PsA is a heterogeneous disease regarding clinical presentation and treatment response. If patients presenting with arthritis first are really a different subgroup, then treatment response and prognosis could also be different. Indeed, in our cohort, achieving minimal disease activity (MDA) was statistically less frequent in patients with arthritis first.” said Prof. Umut Kalyoncu (Hacettepe University, Turkey).
In the study, data on demographic characteristics, family history of psoriatic disease, types of skin psoriasis, site of skin psoriasis onset, and components of PsA ever observed were extracted. Patient characteristics were divided in 3 groups: arthritis-first, psoriasis-first, and synchronous, the latter indicating the onset of skin and joint disease within 12 months. The study’s primary outcome was the absolute time elapsed in months after skin disease to arthritis, with negative values indicating arthritis onset before psoriasis. A total of 1,631 patients were included in the study: 71 who had arthritis first, 309 with synchronous onset, and 1,251 who had psoriasis first.
Data showed that the age of psoriasis onset, not that of arthritis, determined if arthritis or psoriasis would appear first. Pustular psoriasis was associated with a 2-year shorter time interval after psoriasis to arthritis, whereas nail involvement, plaque psoriasis, or family history of psoriasis were associated with an increased delay from psoriasis to arthritis, by approximately 2 years for each factor. “Starting age of psoriasis is particularly important, because it depends on the genetic background,” said Prof. Kalyoncu. “Early-onset psoriasis is strongly associated with HLA-Cw06. However, late-onset psoriasis is not associated with it. In our study, arthritis first was highly related with late-onset psoriasis. This means arthritis-first patients may be a different subgroup of PsA, and treatment response could be worse in these patients as well. If these results are confirmed in other well-defined PsA cohorts, we may have determined a subgroup of this highly heterogeneous disease.”
- Kalyoncu U et al. Abstract 2854. ACR 2019, 9-13 November, Atlanta (GA/USA).
Posted on
Previous Article
« Hand OA: low-dose corticosteroids improve symptoms Next Article
Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib »
« Hand OA: low-dose corticosteroids improve symptoms Next Article
Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib »
Table of Contents: ACR 2019
Featured articles
Late-Breaking Abstracts
Lowest risk of infection after therapy with an IL-12/IL-23 blocker
Calcium pyrophosphate deposition disease: an independent risk factor for cardiovascular complications
Proteome abnormalities improve prediction of RA development
RA patients in remission benefit from continued therapy with conventional DMARDs
Selective IL-23 blocker shows remarkable efficacy in patients with psoriatic arthritis
Corticosteroid therapy in GCA: higher platelets – lower relapse rate
Spotlight on Rheumatoid Arthritis
Filgotinib promising in RA patients naïve to methotrexate
Sustained efficacy of monotherapy with upadacitinib after 48 weeks
Biologics show similar activity in patients with elderly-onset RA
Tocilizumab outperforms rituximab in RA patients with low level of synovial B cell infiltration
Treatment decisions should not be guided by ultrasound findings
Cancer treatment with checkpoint inhibitors in RA patients?
What is Hot in Systemic Lupus Erythematosus
Anifrolumab succeeds in second phase 3 trial in SLE
Depression closely related to fatigue in SLE patients
Spondyloarthritis – The Beat Goes On
Psoriasis onset determines sequence of symptoms
Higher psychiatric comorbidity in women with PsA
JAK1 inhibition shows remarkable efficacy in AS
CARDAS study shows increased prevalence of cardiac valvular disorders in AS patients
Osteoarthritis – State-of-the-Art
Hand OA: low-dose corticosteroids improve symptoms
Opioids: no quality of life benefits for OA patients
Walking speed is a predictor of mortality in patients with knee OA
Reproductive Issues in Rheumatic Disease
Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib
Prevention of congenital heart block may be possible with hydroxychloroquine
TNFi for RA during pregnancy – to stop or not to stop?
Vasculitis – Novel Treatment Modalities
Rituximab maintenance superior to azathioprine in ANCA-associated vasculitis
Prolonged remission after stop of tocilizumab for patients with giant cell arteritis
Best of the Posters
Antifibrotic therapy slows disease progression independent of corticosteroid use
Fibromyalgia patients often experienced abuse in childhood
Related Articles
February 4, 2020
TNFi for RA during pregnancy – to stop or not to stop?
February 4, 2020
Filgotinib promising in RA patients naïve to methotrexate
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com